Global Biologic Medications for Psoriasis 麻豆原创 Growth 2024-2030

Publication ID:

LPI11242210

Publication Date:

November 19, 2024

Pages:

135

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Biologic medications for psoriasis are advanced therapeutic agents derived from living organisms that specifically target and modulate the immune system's activity involved in the disease.These medications are typically used for moderate to severe psoriasis and are administered through injections or infusions.
The global Biologic Medications for Psoriasis market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淏iologic Medications for Psoriasis Industry Forecast鈥� looks at past sales and reviews total world Biologic Medications for Psoriasis sales in 2023, providing a comprehensive analysis by region and market sector of projected Biologic Medications for Psoriasis sales for 2024 through 2030. With Biologic Medications for Psoriasis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biologic Medications for Psoriasis industry.
This Insight Report provides a comprehensive analysis of the global Biologic Medications for Psoriasis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biologic Medications for Psoriasis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Biologic Medications for Psoriasis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biologic Medications for Psoriasis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biologic Medications for Psoriasis.
United States market for Biologic Medications for Psoriasis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Biologic Medications for Psoriasis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Biologic Medications for Psoriasis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Biologic Medications for Psoriasis players cover Bristol-Myers Squibb, Amgen, Tiefenbacher Pharmaceuticals, UCB, Janssen Biotech, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Biologic Medications for Psoriasis market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
TNF-伪 Inhibitors
Interleukin Inhibitors
Tyrosine Kinase Inhibitors
Phosphodiesterase Inhibitors
Other
Segmentation by Application:
Hospital and Clinic
Retail Pharmacies
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bristol-Myers Squibb
Amgen
Tiefenbacher Pharmaceuticals
UCB
Janssen Biotech
Eli Lilly
AbbVie Biotechnology
Dalian Yawei Pharmaceutical
Novartis
Ortho Dermatologics
LEO Pharma
Kyowa Kirin
Boehringer Ingelheim Pharmaceuticals
Pfizer
Samsung Bioepis
Qilu Pharmaceutical
Hanwha Chemical
China Medical System
Key Questions Addressed in this Report
What is the 10-year outlook for the global Biologic Medications for Psoriasis market?
What factors are driving Biologic Medications for Psoriasis market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Biologic Medications for Psoriasis market opportunities vary by end market size?
How does Biologic Medications for Psoriasis break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Biologic Medications for Psoriasis Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Biologic Medications for Psoriasis by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Biologic Medications for Psoriasis by Country/Region, 2019, 2023 & 2030
2.2 Biologic Medications for Psoriasis Segment by Type
2.2.1 TNF-伪 Inhibitors
2.2.2 Interleukin Inhibitors
2.2.3 Tyrosine Kinase Inhibitors
2.2.4 Phosphodiesterase Inhibitors
2.2.5 Other
2.3 Biologic Medications for Psoriasis Sales by Type
2.3.1 Global Biologic Medications for Psoriasis Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Biologic Medications for Psoriasis Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Biologic Medications for Psoriasis Sale Price by Type (2019-2024)
2.4 Biologic Medications for Psoriasis Segment by Application
2.4.1 Hospital and Clinic
2.4.2 Retail Pharmacies
2.4.3 Other
2.5 Biologic Medications for Psoriasis Sales by Application
2.5.1 Global Biologic Medications for Psoriasis Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Biologic Medications for Psoriasis Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Biologic Medications for Psoriasis Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Biologic Medications for Psoriasis Breakdown Data by Company
3.1.1 Global Biologic Medications for Psoriasis Annual Sales by Company (2019-2024)
3.1.2 Global Biologic Medications for Psoriasis Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Biologic Medications for Psoriasis Annual Revenue by Company (2019-2024)
3.2.1 Global Biologic Medications for Psoriasis Revenue by Company (2019-2024)
3.2.2 Global Biologic Medications for Psoriasis Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Biologic Medications for Psoriasis Sale Price by Company
3.4 Key Manufacturers Biologic Medications for Psoriasis Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Biologic Medications for Psoriasis Product Location Distribution
3.4.2 Players Biologic Medications for Psoriasis Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Biologic Medications for Psoriasis by Geographic Region
4.1 World Historic Biologic Medications for Psoriasis 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Biologic Medications for Psoriasis Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Biologic Medications for Psoriasis Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Biologic Medications for Psoriasis 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Biologic Medications for Psoriasis Annual Sales by Country/Region (2019-2024)
4.2.2 Global Biologic Medications for Psoriasis Annual Revenue by Country/Region (2019-2024)
4.3 Americas Biologic Medications for Psoriasis Sales Growth
4.4 APAC Biologic Medications for Psoriasis Sales Growth
4.5 Europe Biologic Medications for Psoriasis Sales Growth
4.6 Middle East & Africa Biologic Medications for Psoriasis Sales Growth
5 Americas
5.1 Americas Biologic Medications for Psoriasis Sales by Country
5.1.1 Americas Biologic Medications for Psoriasis Sales by Country (2019-2024)
5.1.2 Americas Biologic Medications for Psoriasis Revenue by Country (2019-2024)
5.2 Americas Biologic Medications for Psoriasis Sales by Type (2019-2024)
5.3 Americas Biologic Medications for Psoriasis Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biologic Medications for Psoriasis Sales by Region
6.1.1 APAC Biologic Medications for Psoriasis Sales by Region (2019-2024)
6.1.2 APAC Biologic Medications for Psoriasis Revenue by Region (2019-2024)
6.2 APAC Biologic Medications for Psoriasis Sales by Type (2019-2024)
6.3 APAC Biologic Medications for Psoriasis Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Biologic Medications for Psoriasis by Country
7.1.1 Europe Biologic Medications for Psoriasis Sales by Country (2019-2024)
7.1.2 Europe Biologic Medications for Psoriasis Revenue by Country (2019-2024)
7.2 Europe Biologic Medications for Psoriasis Sales by Type (2019-2024)
7.3 Europe Biologic Medications for Psoriasis Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Biologic Medications for Psoriasis by Country
8.1.1 Middle East & Africa Biologic Medications for Psoriasis Sales by Country (2019-2024)
8.1.2 Middle East & Africa Biologic Medications for Psoriasis Revenue by Country (2019-2024)
8.2 Middle East & Africa Biologic Medications for Psoriasis Sales by Type (2019-2024)
8.3 Middle East & Africa Biologic Medications for Psoriasis Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Biologic Medications for Psoriasis
10.3 Manufacturing Process Analysis of Biologic Medications for Psoriasis
10.4 Industry Chain Structure of Biologic Medications for Psoriasis
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Biologic Medications for Psoriasis Distributors
11.3 Biologic Medications for Psoriasis Customer
12 World Forecast Review for Biologic Medications for Psoriasis by Geographic Region
12.1 Global Biologic Medications for Psoriasis 麻豆原创 Size Forecast by Region
12.1.1 Global Biologic Medications for Psoriasis Forecast by Region (2025-2030)
12.1.2 Global Biologic Medications for Psoriasis Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Biologic Medications for Psoriasis Forecast by Type (2025-2030)
12.7 Global Biologic Medications for Psoriasis Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Bristol-Myers Squibb
13.1.1 Bristol-Myers Squibb Company Information
13.1.2 Bristol-Myers Squibb Biologic Medications for Psoriasis Product Portfolios and Specifications
13.1.3 Bristol-Myers Squibb Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Bristol-Myers Squibb Main Business Overview
13.1.5 Bristol-Myers Squibb Latest Developments
13.2 Amgen
13.2.1 Amgen Company Information
13.2.2 Amgen Biologic Medications for Psoriasis Product Portfolios and Specifications
13.2.3 Amgen Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Amgen Main Business Overview
13.2.5 Amgen Latest Developments
13.3 Tiefenbacher Pharmaceuticals
13.3.1 Tiefenbacher Pharmaceuticals Company Information
13.3.2 Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Product Portfolios and Specifications
13.3.3 Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Tiefenbacher Pharmaceuticals Main Business Overview
13.3.5 Tiefenbacher Pharmaceuticals Latest Developments
13.4 UCB
13.4.1 UCB Company Information
13.4.2 UCB Biologic Medications for Psoriasis Product Portfolios and Specifications
13.4.3 UCB Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 UCB Main Business Overview
13.4.5 UCB Latest Developments
13.5 Janssen Biotech
13.5.1 Janssen Biotech Company Information
13.5.2 Janssen Biotech Biologic Medications for Psoriasis Product Portfolios and Specifications
13.5.3 Janssen Biotech Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Janssen Biotech Main Business Overview
13.5.5 Janssen Biotech Latest Developments
13.6 Eli Lilly
13.6.1 Eli Lilly Company Information
13.6.2 Eli Lilly Biologic Medications for Psoriasis Product Portfolios and Specifications
13.6.3 Eli Lilly Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Eli Lilly Main Business Overview
13.6.5 Eli Lilly Latest Developments
13.7 AbbVie Biotechnology
13.7.1 AbbVie Biotechnology Company Information
13.7.2 AbbVie Biotechnology Biologic Medications for Psoriasis Product Portfolios and Specifications
13.7.3 AbbVie Biotechnology Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 AbbVie Biotechnology Main Business Overview
13.7.5 AbbVie Biotechnology Latest Developments
13.8 Dalian Yawei Pharmaceutical
13.8.1 Dalian Yawei Pharmaceutical Company Information
13.8.2 Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Product Portfolios and Specifications
13.8.3 Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Dalian Yawei Pharmaceutical Main Business Overview
13.8.5 Dalian Yawei Pharmaceutical Latest Developments
13.9 Novartis
13.9.1 Novartis Company Information
13.9.2 Novartis Biologic Medications for Psoriasis Product Portfolios and Specifications
13.9.3 Novartis Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Novartis Main Business Overview
13.9.5 Novartis Latest Developments
13.10 Ortho Dermatologics
13.10.1 Ortho Dermatologics Company Information
13.10.2 Ortho Dermatologics Biologic Medications for Psoriasis Product Portfolios and Specifications
13.10.3 Ortho Dermatologics Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Ortho Dermatologics Main Business Overview
13.10.5 Ortho Dermatologics Latest Developments
13.11 LEO Pharma
13.11.1 LEO Pharma Company Information
13.11.2 LEO Pharma Biologic Medications for Psoriasis Product Portfolios and Specifications
13.11.3 LEO Pharma Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 LEO Pharma Main Business Overview
13.11.5 LEO Pharma Latest Developments
13.12 Kyowa Kirin
13.12.1 Kyowa Kirin Company Information
13.12.2 Kyowa Kirin Biologic Medications for Psoriasis Product Portfolios and Specifications
13.12.3 Kyowa Kirin Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Kyowa Kirin Main Business Overview
13.12.5 Kyowa Kirin Latest Developments
13.13 Boehringer Ingelheim Pharmaceuticals
13.13.1 Boehringer Ingelheim Pharmaceuticals Company Information
13.13.2 Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Product Portfolios and Specifications
13.13.3 Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Boehringer Ingelheim Pharmaceuticals Main Business Overview
13.13.5 Boehringer Ingelheim Pharmaceuticals Latest Developments
13.14 Pfizer
13.14.1 Pfizer Company Information
13.14.2 Pfizer Biologic Medications for Psoriasis Product Portfolios and Specifications
13.14.3 Pfizer Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Pfizer Main Business Overview
13.14.5 Pfizer Latest Developments
13.15 Samsung Bioepis
13.15.1 Samsung Bioepis Company Information
13.15.2 Samsung Bioepis Biologic Medications for Psoriasis Product Portfolios and Specifications
13.15.3 Samsung Bioepis Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Samsung Bioepis Main Business Overview
13.15.5 Samsung Bioepis Latest Developments
13.16 Qilu Pharmaceutical
13.16.1 Qilu Pharmaceutical Company Information
13.16.2 Qilu Pharmaceutical Biologic Medications for Psoriasis Product Portfolios and Specifications
13.16.3 Qilu Pharmaceutical Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Qilu Pharmaceutical Main Business Overview
13.16.5 Qilu Pharmaceutical Latest Developments
13.17 Hanwha Chemical
13.17.1 Hanwha Chemical Company Information
13.17.2 Hanwha Chemical Biologic Medications for Psoriasis Product Portfolios and Specifications
13.17.3 Hanwha Chemical Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Hanwha Chemical Main Business Overview
13.17.5 Hanwha Chemical Latest Developments
13.18 China Medical System
13.18.1 China Medical System Company Information
13.18.2 China Medical System Biologic Medications for Psoriasis Product Portfolios and Specifications
13.18.3 China Medical System Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 China Medical System Main Business Overview
13.18.5 China Medical System Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.